Vertex Pharmaceuticals VRTX
$547.09 +$4.59 (+0.85%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $548.00 +0.17%
Open$531.53
Prev close$542.50
Day range$531.53 – $548.76
Volume1.27M
Market cap$138.71B
P/E (TTM)35.2
Dividend yield–
VRTX Stock News
Headlines matching Vertex Pharmaceuticals or the VRTX ticker, most recent first.
- News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
- Vertex Pharmaceuticals Names Jonathan Poole Chief Financial Officer, Effective Jan. 1 VRTX
- BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
- UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $615 Positive
- Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $608
- A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $617
- A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $672
- Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE) Positive
- Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $665 Positive
- Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
- Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
- Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $558
- Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $665
- J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $560 Positive
- Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
No comments yet — be the first to weigh in on VRTX.
Sign in to join the discussion.